Why I’d follow Neil Woodford and sell this FTSE 100 stock

G A Chester reveals his concerns about the valuation and prospects of a popular FTSE 100 (INDEXFTSE:UKX) stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Veteran fund manager Neil Woodford sold all his shares in AstraZeneca (LSE: AZN) earlier this year. The FTSE 100 pharma giant had previously been one of his core holdings.

There were two reasons behind the sale. He needed to raise capital to meet redemptions from his under-performing funds and he also wanted to increase his exposure to domestically-focused companies like Lloyds and a number of the UK’s house-builders. He reckoned the investment thesis for AstraZeneca was still appealing but that there was even greater upside potential in the stocks he moved into.

Credibility deficit

I’ve been positive on the investment case for AstraZeneca for a good number of years. However, I’ve been reviewing my take on the valuation and prospects of the company in recent months, following the release of its annual results in February.

Should you invest £1,000 in Alpha Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Alpha Group made the list?

See the 6 stocks

In the summer of 2014, when fighting off a 5,500p takeover bid from US giant Pfizer, AstraZeneca’s chief executive, Pascal Soriot, made a couple of pledges. He said falling revenues would reverse and in 2017 be back up to the level of 2013 ($25.7bn). This didn’t happen. The actual revenue delivered in 2017 was $22.5bn. City analysts now don’t expect it to surpass the 2013 level until 2020.

The other pledge Soriot made back in 2014 was that the company would be delivering annual revenue in excess of $45bn by 2023. This now looks far-fetched to me and almost certainly another instance of the chief executive over-promising and under-delivering. As a result, he’s built up a sizeable credibility deficit in my book.

Problematic future

In the halcyon days of the first decade of the century, AstraZeneca was consistently making a return on capital employed (ROCE) of a mid-to-high 20s percentage. It even reached above 30% in some years. However, by 2013 it had fallen to below 10% and by 2014 to below 5%. The company made some progress on ROCE in 2015 (7.8%) and 2016 (9%) but 2017 saw the positive trend reverse with it falling back to 6.3%.

My previous optimism about AstraZeneca being able to return to a high ROCE has been further tempered by a two-part blogpost, ‘Pharma’s broken business model,’ by Kelvin Stott, director of R&D portfolio management at Novartis.

Dr Stott addressed the issue of entrenched falling returns on R&D investment and argued that this won’t be overcome by many of pharma’s current strategies, including continuous improvement, new discovery technologies, in-licensing, precision medicine, big data and artificial intelligence. While his work didn’t go uncriticised, I do see AstraZeneca’s future as more problematic than the bull case would have us believe. In particular, I reckon that returns for shareholders are less certain and have more downside risk than I previously thought.

Current valuation

Given my concerns about management under-delivering on its revenue projections, last year’s fall-back in ROCE and the industry-wide problem of falling returns on R&D investment, I don’t believe the company’s current share price and valuation are appealing.

The price is around the 5,500p Pfizer offered four years ago and the valuation is a rich 22 times current-year forecast earnings with a below-Footsie-average dividend yield of 3.9%. Although the shares are down from last month’s high of over 6,000p, I continue to rate the stock a ‘sell’ at the present level.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Google office headquarters
Investing Articles

$1bn a day! This S&P 500 share still looks like a stock market bargain after Q1 earnings

The owner of Google and YouTube just announced strong results to the stock market, including another massive $70bn share buyback.

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

3 cheap FTSE 100 stocks with big dividends to consider buying right now

Sector weakness in some FTSE 100 industries has also left some of my long-term favourite stocks offering attractive dividend yields.

Read more »

Growth Shares

Forecast: £1,000 invested in Rolls-Royce shares could be worth this much by next year

Jon Smith talks through both his opinion and analysts’ forecasts when trying to predict where Rolls-Royce shares could head from…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

£5,000 invested in Lloyds shares 5 years ago is now worth…

The price of Lloyds shares has more than doubled over the past five years. However, our writer’s cautious about the…

Read more »

Investing Articles

Up 58% in a year, the BT share price could be the FTSE 100 target to beat in 2025

The BT share price has been steadily climbing back since newish boss Allison Kirkby came on board. Is the new…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£10,000 invested in Nvidia stock 5 years ago is now worth…

Even after the Nvidia stock falls of the past couple of months, its five-year performance remains stunning. And it could…

Read more »

artificial intelligence investing algorithms
Investing Articles

I asked ChatGPT for the best UK stocks to buy for my portfolio in the market sell-off. Here’s what it said

When Edward Sheldon asked the generative AI app for the best stocks to buy amid the market pullback, he was…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Could now be a rewarding moment to buy shares?

Christopher Ruane's looking for shares to buy in a turbulent market. But while he's focused on quality, he's equally interested…

Read more »